Significant expression of IGFBP2 in breast cancer compared with benign lesions.
about
IGF-Binding Protein 2 - Oncogene or Tumor Suppressor?Insulin-like growth factor system in cancer: novel targeted therapiesDevelopment of IGF signaling antibody arrays for the identification of hepatocellular carcinoma biomarkersGenome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.Linking patient outcome to high throughput protein expression data identifies novel regulators of colorectal adenocarcinoma aggressivenessIntegration of Breast Cancer Secretomes with Clinical Data Elucidates Potential Serum Markers for Disease Detection, Diagnosis, and Prognosis.Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells.Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3Expression of insulin-like growth factor binding protein-2 in gastric carcinoma and its relationship with cell proliferation.Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts.Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival.Differentially regulated splice variants and systems biology analysis of Kaposi's sarcoma-associated herpesvirus-infected lymphatic endothelial cells.Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent.Noncoding RNAs that associate with YB-1 alter proliferation in prostate cancer cells.IGFBP-2 and -5: important regulators of normal and neoplastic mammary gland physiologyInsulin-like growth factor binding protein 2 promotes glioma development and progressionIGFBP2 potentiates nuclear EGFR-STAT3 signaling.Autoantibodies against insulin-like growth factor‑binding protein-2 as a serological biomarker in the diagnosis of lung cancerRegulation of protumorigenic pathways by insulin like growth factor binding protein2 and its association along with β-catenin in breast cancer lymph node metastasis.Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer.Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science.Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24.Genome-wide screening of indicator genes for assessing the potential carcinogenic risk of Nanjing city drinking water.Role of insulin-like growth factor-binding proteins in the pathophysiology and tumorigenesis of gastroesophageal cancers.IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells.IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription.Long non-coding RNA HOTAIR promotes cell migration by upregulating insulin growth factor-binding protein 2 in renal cell carcinoma.Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity.IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas.Adeno-associated virus type 2-mediated gene transfer of a short hairpin-RNA targeting human IGFBP-2 suppresses the proliferation and invasion of MDA-MB-468 cells.Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics.Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies.
P2860
Q27003443-40C208E9-55B3-40DE-8C5D-5E4438AFF4C9Q28081603-3A74F06E-B8B9-48C1-B1FB-3537F84AD748Q28484376-11A7EEDF-FA6F-4B00-9969-D89AE0AF4786Q29417100-7414BEA5-262F-44F9-9FC5-1A9A49AFFC1FQ30975797-1C9A07BA-C7E8-4A67-BEB6-B07637AAF197Q31111254-0EBB9B1E-4A47-4965-8D54-621DB0A8BD72Q33349898-BCB5017F-400D-45F6-868B-FF93ACC6D1E8Q33745176-3B88712C-AA42-43D3-97DA-43BD0AFA1A0BQ33869094-534B2F6E-351F-40B5-8A82-3077CA2782BDQ34145178-0C7EB5D0-EA33-46BE-99F5-709D60829605Q34391968-C054BA14-8C62-4B8B-B448-87C8BB4875B7Q34999407-4638E347-BD6A-4C78-A8EB-2CC33BAD7E4CQ35198402-CE39E6A6-F5AD-46F5-A13E-22225394E75FQ35524233-B18E1C79-70CC-4A0D-986C-47F9035AD1C3Q35621452-F881EF7C-D7B8-4863-95CD-7F6241243CFDQ35690638-1C137FE1-4E8B-47F7-B34B-18054BACCFEBQ35880328-6BFB1399-D42D-49B0-82BF-7810D424014AQ36189855-8C909D2F-0E09-437D-BFE8-CA668E7DECF9Q36642867-18E779E4-308B-47AE-9296-DAE00D4403F2Q36972353-C25A4D60-864E-452B-8B77-FDABA5093C5AQ37001399-2F43A817-6E07-4B29-A3AA-AF5BF72FB213Q37348411-E3D86DE8-412C-479C-8309-8D816AFA861EQ37362627-D8BFC2EC-3D99-4E30-A8A0-20BA658D474BQ37395331-D5C7BD30-7BE2-4466-B45A-725D900CC5D3Q37396281-049635A3-77E2-440D-A4D1-0E23BDBB5C80Q37418923-297A3603-C27A-4EC6-925D-0000E281FFA3Q37720601-6964E8D2-3129-4D3C-97EA-24D5792C10D5Q38302138-97F000C6-9802-4CB1-8DA4-EC39BB8ABEF5Q38502919-3EA07F19-8B6E-4DA5-97D8-A9F669C06FE9Q38586626-BA1A76B5-E082-4841-8DF8-1C56D54B7043Q39189621-A6A113CD-9A08-4D98-93D8-B5C395C06E93Q39718565-8199EC24-9577-4672-A637-EE4B7F2B77F8Q41696965-C8567515-198D-406D-9BC2-70B021614944Q42365291-4C67C763-529D-4EE0-8F94-6953BFD2DEC8Q46676464-F09979AA-612B-49B7-9DAA-D16D9084E7CCQ47552079-215CBE59-0BDC-4996-812F-C0490CF6DD1AQ52598780-1A74BE1E-35E7-4174-9410-49B00185DC85Q55462258-4DCCD445-4548-49E7-910C-96AF90F1E567
P2860
Significant expression of IGFBP2 in breast cancer compared with benign lesions.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Significant expression of IGFBP2 in breast cancer compared with benign lesions.
@ast
Significant expression of IGFBP2 in breast cancer compared with benign lesions.
@en
type
label
Significant expression of IGFBP2 in breast cancer compared with benign lesions.
@ast
Significant expression of IGFBP2 in breast cancer compared with benign lesions.
@en
prefLabel
Significant expression of IGFBP2 in breast cancer compared with benign lesions.
@ast
Significant expression of IGFBP2 in breast cancer compared with benign lesions.
@en
P2093
P2860
P356
P1476
Significant expression of IGFBP2 in breast cancer compared with benign lesions.
@en
P2093
E Richardsen
H Stalsberg
L-T Busund
T Bjørnsen
P2860
P304
P356
10.1136/JCP.2004.020834
P407
P577
2005-04-01T00:00:00Z